MAB Discovery GmbH:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:MAB Discovery GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11210
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:23
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
MAB Discovery GmbH (MAB Discovery) is a drug discovery and development company that offers novel antibody therapeutics. The company produces monoclonal antibodies derived from rabbits and rats by employing biochemical and cellular based screens. It relies on natural immune response and B cell cloning techniques for the production of monoclonals with unprecedented epitope coverage and potency. MAB Discovery’s B-cells are cloned by fluorescence activated cell sorting and deposited as single cells into proprietary growth medium. It also undertakes projects from immunization, high throughput screening, assay development, and functional characterization. The company partners with biotech and pharmaceutical companies for the discovery and generation of monoclonal antibodies. MAB Discovery is headquartered in Neuried, Germany.

MAB Discovery GmbH – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
MAB Discovery GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
MAB Discovery Enters into Agreement with Cullinan Oncology 10
MAB Discovery Enters into Agreement with BioNTech 11
MAB Discovery Enters into Research Agreement with Synthon for Antibodies 12
MAB Discovery Enters into Research Agreement with BioNTech for Monoclonal Antibody Products 13
MAB Discovery Enters into Research Agreement with Genmab for Therapeutic Antibody Products 14
MAB Discovery Enters Into Research Agreement With Pharma Company 15
MAB Discovery Enters Into Research Agreement With US Biotech Company 16
Licensing Agreements 17
Fusion Antibodies Plans to Enter into Licensing Agreement with MAB Discovery 17
Sanofi Enters into Licensing Agreement with MAB Discovery 18
MAB Discovery GmbH – Key Competitors 19
MAB Discovery GmbH – Key Employees 20
MAB Discovery GmbH – Locations And Subsidiaries 21
Head Office 21
Recent Developments 22
Other Significant Developments 22
Jun 20, 2018: Ongoing discussions with MAB Discovery for revised collaboration agreement Advance notice of termination of existing agreement in-line with discussions 22
Appendix 23
Methodology 23
About GlobalData 23
Contact Us 23
Disclaimer 23

List of Tables
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Key Facts 2
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
MAB Discovery GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
MAB Discovery GmbH, Deals By Therapy Area, 2012 to YTD 2018 8
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
MAB Discovery Enters into Agreement with Cullinan Oncology 10
MAB Discovery Enters into Agreement with BioNTech 11
MAB Discovery Enters into Research Agreement with Synthon for Antibodies 12
MAB Discovery Enters into Research Agreement with BioNTech for Monoclonal Antibody Products 13
MAB Discovery Enters into Research Agreement with Genmab for Therapeutic Antibody Products 14
MAB Discovery Enters Into Research Agreement With Pharma Company 15
MAB Discovery Enters Into Research Agreement With US Biotech Company 16
Fusion Antibodies Plans to Enter into Licensing Agreement with MAB Discovery 17
Sanofi Enters into Licensing Agreement with MAB Discovery 18
MAB Discovery GmbH, Key Competitors 19
MAB Discovery GmbH, Key Employees 20

List of Figures
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
MAB Discovery GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[MAB Discovery GmbH:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Revance Therapeutics Inc (RVNC)-医療機器分野:企業M&A・提携分析
    Summary Revance Therapeutics Inc (Revance Therapeutics) develops, manufactures and commercializes novel botulinum toxin products. The company’s product candidate includes RT002, an injectable formulation of botulinum toxin type for the treatment of glabellar lines, cervical dystonia, and plantar fas …
  • Antibe Therapeutics Inc (ATE)-医療機器分野:企業M&A・提携分析
    Summary Antibe Therapeutics Inc (Antibe) is a biotechnology company that designs and develops drug candidates for chronic pain and inflammation; and regenerative medicine. The company discovers and commercialize novel drugs, biologics and medical devices. It offers lead compound ATB-346, a naproxen …
  • Texas Health Resources:企業の戦略的SWOT分析
    Texas Health Resources - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Jabil Inc (JBL):企業の財務・戦略的SWOT分析
    Jabil Inc (JBL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • OSE Immunotherapeutics (OSE):製薬・医療:M&Aディール及び事業提携情報
    Summary OSE Immunotherapeutics (OSE), formerly OSE Pharma SA is a biotechnology company that discovers and develops immunotherapy products against invasive and metastatic late-stage cancers. The company’s memopi technology is employed in studying the development of treatments for ovarian, colon and …
  • Ajinomoto Co Inc (2802):企業の財務・戦略的SWOT分析
    Ajinomoto Co Inc (2802) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Israel Institute of Technology:製薬・医療:M&Aディール及び事業提携情報
    Summary Israel Institute of Technology (Technion) is a research university that offers science and technology programs. The university offers various undergraduate and graduate programs in biology, biomedical engineering, biotechnology and food engineering, chemical engineering, and medicine and env …
  • ResApp Health Ltd (RAP):企業の製品パイプライン分析
    Summary ResApp Health Ltd (ResApp) formerly, Narhex Life Sciences Limited is a digital health company that develops smartphone applications for the diagnosis and management of respiratory disease. It's digital healthcare solutions assist doctors and patients to diagnose and manage respiratory diseas …
  • FEMSA Comercio, S.A. de C.V.:企業の戦略・SWOT・財務情報
    FEMSA Comercio, S.A. de C.V. - Strategy, SWOT and Corporate Finance Report Summary FEMSA Comercio, S.A. de C.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Brown Brothers Harriman & Co:企業の戦略的SWOT分析
    Brown Brothers Harriman & Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Eldorado Gold Corporation:企業の戦略・SWOT・財務情報
    Eldorado Gold Corporation - Strategy, SWOT and Corporate Finance Report Summary Eldorado Gold Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Electricity Authority of Cyprus:発電所・企業SWOT分析
    Electricity Authority of Cyprus – Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on k …
  • Innate Pharma SA (IPH):企業の財務・戦略的SWOT分析
    Summary Innate Pharma SA (Innate Pharma) is a healthcare products provider that develops immunopharmacology and antibody technology products. The company carries out the discovery and development of therapeutic antibodies for the treatment of cancer and inflammatory diseases. It develops new monoclo …
  • Sumi-Eagle Corp:企業の戦略的SWOT分析
    Sumi-Eagle Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Inditex SA (ITX):企業の財務・戦略的SWOT分析
    Inditex SA (ITX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • The Ultimate Software Group Inc:企業の戦略的SWOT分析
    The Ultimate Software Group Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • RH Petrogas Ltd (T13):石油・ガス:M&Aディール及び事業提携情報
    Summary RH Petrogas Ltd (RH Petrogas) is an oil and gas company that explores, develops and produces oil and gas resources. The company’s properties include FUYU 1 block, Basin and Island PSC, and SK331 PSC. Its FUYU 1 block property is located in south-east of the Fuyu oilfield in the Jilin provinc …
  • MGM China Holdings Ltd:戦略・SWOT・企業財務分析
    MGM China Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary MGM China Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Lexmark International Inc:企業の戦略的SWOT分析
    Lexmark International Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • eLong, Inc.:企業の戦略・SWOT・財務情報
    eLong, Inc. - Strategy, SWOT and Corporate Finance Report Summary eLong, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆